Biohaven said in a recent regulatory filing that the FDA has accepted its new drug application for treatment and prevention of migraine headaches.
The filing indicates that Biohaven’s drug candidate, Rimegepant, had priority review status by the FDA. That means the FDA’s goal is to take action on an application within 6 months and a decision on whether the drug should be approved could come by the end of the first quarter of 2020. more